Pfizer announced positive progression-free survival results from the BREAKWATER trial evaluating Braftovi in combination with cetuximab and Folfiri in previously untreated metastatic colorectal cancer patients with BRAF V600E mutation.
Pfizer announced positive results from Cohort 3 of the Phase 3 BREAKWATER trial, showing BRAFTOVI combined with cetuximab and FOLFIRI significantly improved progression-free survival in previously untreated BRAF V600E-mutant metastatic colorectal cancer patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07472868 |
Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer |
NOT_YET_RECRUITING | PHASE3 |
| NCT06242418 |
CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial) |
RECRUITING | PHASE2 |
| NCT05201430 |
Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer |
RECRUITING | PHASE3 |
| NCT04832776 |
FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases |
RECRUITING | PHASE2 |
| NCT04380337 |
Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer |
COMPLETED | PHASE2 |
| NCT03671252 |
Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation |
RECRUITING | PHASE3 |
| NCT03504618 |
Research on the Treatment of Metastatic Colon Cancer Patients Treated by FOLFOXIRI |
COMPLETED | |
| NCT03487939 |
Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer |
UNKNOWN | PHASE2 |
| NCT03484221 |
Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer |
UNKNOWN | PHASE2 |
| NCT03484195 |
Neoadjuvant FOLFOXIRI Chemotherapy in Patients With Locally Advanced Colon Cancer |
UNKNOWN | PHASE2 |
